ISRCTN69736109已完成未知
A pilot study on the effects of adding C-reactive protein point-of-care testing in the management of acutely ill children in primary care
niversity of Oxford (UK)0 个研究点目标入组 700 人开始时间: 2013年7月22日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 700
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Participant/parent or guardian is willing and able to give informed consent for participation in the study.
- •2. Male or Female, aged 1 month to 16 years.
- •3. Presenting to out-of-hours with an acute illness of a maximum of 5 days.
- •4. A subset of children, i.e. Those with a body temperature >=38°C, will be randomised to CRP or no CRP testing.
排除标准
- •1. Acute trauma
- •2. Clinically unstable warranting immediate care
- •3. Prior inclusion in the study
- •4. Prior inclusion in another clinical trial of an investigational medicinal product in the last 90 days or any other research in the last 30 days
研究者
相似试验
进行中（未招募）
不适用
A phase IIa study to characterize the effects of CCL2 inhibition with the Spiegelmer® NOX-E36 in patients with type 2 diabetes mellitus and albuminuriadiabetes mellitus type II and albuminuriaMedDRA version: 14.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: PTClassification code 10001580Term: AlbuminuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2011-005710-11-DEOXXON Pharma AG75
进行中（未招募）
不适用
A phase IIa study to characterize the effects of CCL2 inhibition with the Spiegelmer® NOX-E36 in patients with type 2 diabetes mellitus and albuminuriadiabetes mellitus type II and albuminuriaMedDRA version: 14.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: PTClassification code 10001580Term: AlbuminuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2011-005710-11-CZOXXON Pharma AG75
进行中（未招募）
不适用
A phase IIa study to characterize the effects of CCL2 inhibition with the Spiegelmer® NOX-E36 in patients with type 2 diabetes mellitus and albuminuriadiabetes mellitus type II and albuminuriaMedDRA version: 14.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: PTClassification code 10001580Term: AlbuminuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2011-005710-11-HUOXXON Pharma AG75
进行中（未招募）
不适用
A phase IIa study to characterize the effects of CCL2 inhibition with the Spiegelmer® NOX-E36 in patients with type 2 diabetes mellitus and albuminuriaEUCTR2011-005710-11-PLOXXON Pharma AG75
已完成
不适用
A pilot study to investigate the effect of reactivity to brief alcohol assessment on subsequent consumption, problems and dependenceHazardous drinkingMental and Behavioural DisordersExcessive alcohol consumptionISRCTN22264953King's College London (UK)400